Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers December 1, 2015
Pharmacy Choice - News - Front Page Healthcare News - December 1, 2015

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/1/15 - Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that a late breaking abstract describing results from the ACE-083 Phase 1 clinical trial has been selected for an oral plenary presentation.
12/1/15 - Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines Agency granted Orphan Drug Designation for ADXS-HER2 for the treatment of osteosarcoma.. Receiving Orphan Drug Designation from the EMA is another significant step forward for Advaxis as we continue to advance ADXS-HER
12/1/15 - Bill Kazmaier, Hall of Fame member and 3-time World's Strongest Man, shares the instant benefits of the 2015 FDA cleared Dolphin Neurostim device
Dolphin Neurostim, the first point locator and stimulator to be cleared by the FDA for over-the-counter use, is now available in the United States enabling patients to treat themselves for the first time at home. Senior Dolphin Instructor: Kelly Armstrong, OTR/L, MPP International author, speaker and educator Kelly Armstrong has been an Occupatio
12/1/15 - Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers at the 57th Annual Meeting %7E Exposition of the American Society of Hematology [Global Data Point]
Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in patients with relapsed or refractory multiple myeloma; for Opdivo for an investigational use in patients with R/R classical Hodgkin lymphoma; and for Sprycel in chronic myeloid leukemia.&# x0D;. Results from the primary analysis of the ELOQUENT-
12/1/15 - Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that on November 30, 2015 the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to Kevetrin for the treatment of...
12/1/15 - Coverage For MiMedx Allografts Increases To Over 170 Million Commercial Health Plan Lives
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update of its products' coverage by co
12/1/15 - Deciphera Pharmaceuticals to Present at Oppenheimer Annual Healthcare Conference
Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera s President and Chief Executive Officer will present a corporate update at the Oppenheimer 26 th Annual...
12/1/15 - Edmond-Based Drug Company Responds To FDA Requests [Global Data Point]
In October, the FDA recommended that Qualgen cease sterile operations until appropriate corrective actions have been implemented by the facility, and recall all non-expired drugs.&# x0D;. "As soon as we became aware of what the FDA was observing during its September audit, we immediately began correcting the issues." According to Riney, the fact t
12/1/15 - Eisai Announces FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq
Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for review a New Drug Application for a once-daily formulation of its antiobesity agent BELVIQ which has the potential to offer patients the convenience of once-daily treatment.Acceptance of the application indicates that the FDA has found the submission to be..
12/1/15 - FDA approved almost all medical devices in the last year [Chicago Tribune]
The 98 percent approval rate compares to 86 percent last year and 70 percent in 2012, according to recent FDA figures. For the medical-device industry including Chicago names Abbott Laboratories and Baxter International the approvals could translate into billions of dollars worth of new revenue and profits. The higher numbers come as the FDA is
12/1/15 - FDA approves new lung cancer therapy for patients who develop resistance
By a News Reporter-Staff News Editor at Cancer Weekly DENVER- The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's decision to grant accelerated approval for osimertinib, an oral medication for advanced non-small cell lung cancer patients with a specific epidermal growth factor receptor mutat
12/1/15 - First Patient Scanned by Molecular Dynamics' Innovative Whole-Body CZT Digital SPECT/CT
RAMAT GAN, Israel, December 1, 2015/ PRNewswire/. Molecular Dynamics successfully imaged the first patient on the Valiance X12, its whole-body CZT based digital SPECT/CT prototype at the Chaim Sheba Medical Center in Israel. The scan was completed in the Department of Nuclear Medicine at the Chaim Sheba Medical Center and the clinical study is su
12/1/15 - Fish & Richardson Principal Jonathan Singer Named 2015 Life Sciences MVP by Law360
Law360 called Singer "a go-to litigator for drug makers seeking to defend their brand-name prescription drugs from generic challengers" who "helped score a trio of patent victories" for long-time client Allergan Inc. In August 2015, the U.S. Court of Appeals for the Federal Circuit affirmed a win that blocks Allergan's four competitors from selling
12/1/15 - Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol? for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that the U.S. Food and Drug Administration has cleared Galmed's Investigational New Drug application for the ARRIVE Study, a proof-of-concept clinical trial that will
12/1/15 - Guitar Maker Paul Reed Smith and Team of Scientists and Physicians Launch Image and Sound Waveform Technology Company "Digital Harmonic LLC"
By a News Reporter-Staff News Editor at Journal of Technology Legendary guitar maker Paul Reed Smith, founder of PRS Guitars, a team of renowned scientists and physicians and a former Commissioner of the Food and Drug Administration are launching a new technology to develop enhanced sharper x-rays while significantly reducing the amount of radiat
12/1/15 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 66909) - Workshop
EVENT: Health and Human Services Department; Food and Drug Administration holds a workshop titiled "Clinical Trials-Assessing Safety and Efficacy in Diverse Populations," to discuss approaches in clinical trial design and subgroup analyses for therapeutic product development and life-cycle management.
12/1/15 - Health Bites: Can sunscreen ward off medical implant infections? [The Sacramento Bee]
Nov. 30 Every two weeks, we gather some of the most interesting and intriguing studies from health researchers around the world. Possibly, according to a recent University of Michigan study, which finds that a common ingredient in sunscreens could be an effective antibacterial coating for medical implants, such as pacemakers and replacement joint
12/1/15 - Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) 2%
Horizon Pharma plc, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application numb
12/1/15 - ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate technology, today announced the presentation of new preclinical data with the Company s experimental therapies IMGN529 and IMGN779 to be made at the upcoming American Society of Hematology annual meeting to be held December 5
12/1/15 - Investigators from University Medical Center, Erlangen Zero in on Carcinomas (Treatment of perforated colon carcinomas-outcomes of radical surgery)
By a News Reporter-Staff News Editor at Cancer Weekly A new study on Oncology is now available. According to news reporting originating in Erlangen, Germany, by NewsRx journalists, research stated, "When patients present with a perforation of a colon cancer, this situation increases the challenge to treat them properly. The news reporters obtaine
12/1/15 - Lawmakers: LePage administration stymied public health study [Bangor Daily News, Maine]
Nov. 30 AUGUSTA, Maine A legislative committee created to examine how Maine uses $50 million a year in tobacco settlement funding disbanded Monday with its mission unfinished because, according to lawmakers, Gov. The committee created this year by the Legislature voted unanimously to order the Department of Health and Human Services to prod
12/1/15 - MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a Therapeutic for Pancreatic Cancer
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces it has filed an Investigational New Drug Application with the U.S. Food and Drug Administration for the Company's lead fully human antibody product HuMab 5 B1 as a therapeutic agent. Subject to FDA acceptance, MabVax plans to initiate the Phase I cli
12/1/15 - New Breast Cancer Findings Has Been Reported by Researchers at Cancer Hospital (Elevated C1orf63 expression is correlated with CDK10 and predicts...
New Breast Cancer Findings Has Been Reported by Researchers at Cancer Hospital. By a News Reporter-Staff News Editor at Cancer Weekly Fresh data on Oncology are presented in a new report. According to news originating from Shantou, People's Republic of China, by NewsRx correspondents, research stated, "Chromosome 1 open reading frame 63 is locate
12/1/15 - Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033
VBL Therapeutics, today announced the grant of US Patent No. 9,200,056, entitled "A Fas-Chimera Adenovirus Vector" by the United State Patent Office which covers VB-111, VBL's lead drug candidate. It is a strong addition to our Vascular Targeting System portfolio, "said Erez Feige, Ph.D., Vice President of Business Operations of VBL Therapeutics.
12/1/15 - Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, today announced the first patient was dosed in the Phase 2 clinical study of its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator protein. We are pleased to initiate the
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement